openPR Logo
Press release

Hospital-acquired Pneumonia Drugs Market: to reach over by 2020

05-15-2018 07:00 PM CET | Health & Medicine

Press release from: Transparency Market Research

/ PR Agency: Transparency Market Research
Hospital-acquired Pneumonia Drugs Market: to reach over by 2020

Hospital-acquired Pneumonia Drugs Market: Overview

Nosocomial or hospital acquired infections have created numerous complications for patients in hospitals throughout the world, as these infections are caused by multidrug resistant microorganisms, the recuperation of a patient is drastically reduced and accompanied by several comorbidities. Being multidrug resistant, these organisms are immune to the conventional antibiotics hence difficult to treat. Pneumonia is one of the prominent infections caused in hospital premises. Cases of hospital acquired pneumonia are common in immunocompromised patients, post surgical infections, enteral feeding, elderly and infant patients. As hospital acquired pneumonia is mainly caused as a result of prolonged exposure to ventilator air, it is also called as ventilator associated pneumonia. Major causative pathogens include methicillin resistant S. aureus (MRSA), multi drug resistant (MDR) P. aeruginosa, Klebsiella and Acinetobacter. Respiratory Syncytial Virus (RSV) has also been found to be a major causative agent of nosocomial pneumonia in new borne.

Request to View Sample of the Report –

https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1881

Currently there are four drugs authorized for treatment of hospital acquired pneumonia; these include Zosyn (piperacillin/tazobactam), Zyvox (linezolid), Tygacil (tigecycline), and Vibativ (telavancin). Consistent research and development is being conducted in view of introducing more effective treatment options. There are five investigational drugs and one vaccine in stage III clinical trials, while ten other candidates in early stage, which mainly include biological drugs.

Request to View Brochure of the Report –

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1881

Tedizolid phosphate and ceftolozane/tazobactam by Cubist Pharmaceutical, ceftazidime/avibactam by AstraZeneca PLC, amikacin inhale by Bayer Healthcare, plazomicin by Achaogen, Inc. and Synflorix by GlaxoSmithKline are the phase III candidates. Considering the antibacterial efficiency, and current market competition, tedizolid phosphate is expected to be the most preferred drug for treatment of nosocomial pneumonia. Amikacin inhale, an aerosolized drug is intended for sale as a drug device combination. Majority of the drugs in the late stages are biological drugs. Aridis Pharmaceutical holds four investigational drugs against various causative agents of hospital acquired pneumonia, each being monoclonal antibody therapy.

Request For Discount On This Report:

https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=1881

Key companies in the market include Achaogen, Inc., Aridis Pharmaceutical, AstraZeneca PLC, Basilea Pharmaceutica Ltd., Bayer Healthcare, Cubist Pharmaceutical, GlaxoSmithKline, Meiji Seika Pharma Co., Ltd., Merck & Co., and Valneva SE.

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

US Office Contact
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Hospital-acquired Pneumonia Drugs Market: to reach over by 2020 here

News-ID: 1050684 • Views: 421

More Releases from Transparency Market Research

Latest TMR Report Explores Impact of COVID-19 Outbreak on Iron and Steel Market
Global Iron and Steel Market: Overview The iron and steel industry forms the fundamental part of a number of other industries that constitute global trade and economy. History has it that churns and disruptions in the global iron and steel market can have far-reaching impacts on several ancillary industries including but not limited to construction, automotive, chemicals, energy, and heavy engineering. The growth of these application areas, however, also bodes
Latest TMR Report Explores Impact of COVID-19 Outbreak on Air-cooled Heat Exchan …
Air-cooled Heat Exchangers Market: Overview Air-cooled heat exchangers (ACHEs) are used to remove heat generated by a process system, which has no local use. They are typically used when the outlet temperature exceeds the maximum expected ambient air temperature by more than 20°F. They can also be used for smaller differences in temperatures; however, in such cases, they become more expensive than the combination of a water-cooled exchanger and a cooling
Analysis of COVID-19 Crisis-driven Growth Opportunities in Diisobutyl Ketone Mar …
Diisobutyl ketone is a colorless and stable liquid. It emits a mild sweetish menthol odor. Diisobutyl ketone has a high boiling temperature and delivers as a slow evaporating solvent. It has limited solubility in water, but it is miscible with ketones and other alcohols. Diisobutyl ketone provides superior viscosity reduction properties. It reduces surface tension in specific solid coatings. Diisobutyl ketone is highly used in industrial chemistry. It ensures excellent
Analysis of COVID-19 Crisis-driven Growth Opportunities in White Fused Alumina M …
White Fused Alumina Market: Overview Calcined alumina, also known as corundum or alpha alumina, is an essential raw material used in the manufacturing of white fused alumina. White fused alumina is the purest form of alumina, produced by fusing calcined alumina in electric arc furnaces at a temperature of about 2,000°C. White fused alumina possesses excellent properties such as hardness, purity, chemical stability, melting point, and large crystal size. It is

All 5 Releases


More Releases for Pharma

Global Deferasirox Market 2018 - Novartis, Cipla, Sun Pharma, Natco Pharma
Apex Market Reports, recently published a detailed market research study focused on the “Deferasirox Market” across the global, regional and country level. The report provides 360° analysis of “Deferasirox Market” from view of manufacturers, regions, product types and end industries. The research report analyses and provides the historical data along with current performance of the global PP Pipe industry, and estimates the future trend of Deferasirox on the basis of
Big Pharma Outlook 2026
Boston, MA ReportsWorldwide has announced the addition of a new report title Big Pharma Outlook 2026 to its growing collection of premium market research reports. Pharmavitae Analytics casts its eye out to 2026 with challenging trends in healthcare management set to crystallize, Big Pharma will add $29.5bn in revenues out to 2026, generating $351bn in prescription pharmaceuticals at a low single-digit compound annual growth rate (CAGR) of 0.9%. Using in-house sales forecasts,
Clomifene Citrate Market 2017 - Sanofi, Palam Pharma, Bioxera, Zafax Pharma
Apex Research, recently published a detailed market research study focused on the "Clomifene Citrate Market" across the global, regional and country level. The report provides 360° analysis of "Clomifene Citrate Market" from view of manufacturers, regions, product types and end industries. The research report analyses and provides the historical data along with current performance of the global Clomifene Citrate industry, and estimates the future trend of Clomifene Citrate market on
12th World Pharma Congress
Conference Series proudly announces 12th World Pharma Congress for 2017, during October 16-18, at Budapest, Hungary. Pharmaceutical innovation is an orderly, predictable process. Intensive research coverage is resulting in an abundant knowledge of the mechanisms driving drug discovery and development. Pharmaceutical Formulation Market size was USD $147billion in 2015 and is anticipated to reach around USD 175.1 billion by 2018. In USA, the total number of new drugs approved between
12th World Pharma Congress
Conference Series has taken an initiation to conduct International Pharma Congress worldwide. From several years Conference Series has been conducting Pharma Congress conferences in major continents like Europe, America and Asia Pacific. Previous conferences were held in city like USA, with success. Conference Series proudly announces 12th World Pharma Congress for 2017, during October 16-18, at Budapest, Hungary. Pharmaceutical innovation is an orderly, predictable process. Intensive research coverage is resulting
4th African Pharma Congress
In the light of this theme, the conference series aims to provide a forum for international researchers from various areas of pharmaceutical sciences like chemical processing, industrial practice, analytical methods and pharmacological actions by providing a platform for critical analysis of new agenda, and to share latest cutting-edge research findings and results about all aspects of Pharmacy We are honoured to invite pharmacists, researchers, professors, scientific communities, delegates, students, business